The data in the table show that, the exposure ofHBV infection in non vaccinated more than 20%, then vaccinated populations less than 7%.
Conclusion:
The exposure and prevalence rate of HBV infection significant difference in vaccinated and non vaccinated population.
PP-120 Cloning and screening transregulated genes of HBEBP2 by SSH Objective: To screen and identify human genes transactivated by HBEBP2 by constructing a cDNA subtractive library with suppression subtractive hybridization (SSH) technique. Methods: pcDNA3.1( )-myc-his-HBEBP2 was constructed. Then the L02 cells was transfected by pcDNA3.1( )-mychis-HBEBP2 and pcDNA3.1( )-myc-his empty vector, and SSH method was employed to analyze the differentially expressed DNA sequence between the two groups. After restriction enzyme Rsa I digestion, small sizes cDNAs were obtained. Then tester cDNA was divided into two groups and ligated to the specific adaptor 1 and adaptor 2, respectively. Aftertester cDNA was hybridized with driver cDNA twice and underwent two times of nested PCR, the second PCR production was subcloned into pGEM-Teasy plasmid vectors to set up the subtractive library. Amplification of the library was transformed into E. coli. The cDNA was sequenced and analyzed in GenBank with Blastn search after PCR.
Results: The subtractive library of genes transactivated by HBEBP2 was constructed successfully. The amplified library contains 80 positive clones containing 200 bp-1000 bp inserts. Sequence analysis was performed in 26 clones randomly, and the full length sequences were obtained with bioinformatics method. Altogether 7coding sequences were gotten. Conclusions: The obtained sequences may be target genes transactivated by HBEBP2, and some genes coding proteins involved in metabolism, autoimmunity regulation, protein modification, cell cycle regulation. Results: The three SNPs sites showed no significant genotyping/allelic associations with chronic HBV infection. Overall allelic P values: rs10415576, P = 0.0908, OR (95%CI) = 1.1798 (0.9740 1.4291); rs2304204, P = 0.5959, OR (95%CI) = 1.0597 (0.8552 1.3133); rs2304206, P = 0.8372, OR (95%CI) = 1.0250 (0.8097 1.2976). Overall genotype P values: rs10415576, P = 0.2106; rs2304204, P = 0.8458; rs2304206, P = 0.8315. There was no statistically significant difference between chronic HBV infection and controls. Haplotypes generated by these three SNPs did not show significantly difference between the two groups either (P > 0.05). Results: Both in CHB patients and healthy people, TLR-2 decreased significantly (t scores were 4.948 and 3.245, both P values were below 0.05) and B7-H1 increased (t scores were 3.612 and 2.341, both P values were below 0.05) and IFN-g decreased significantly (CHB group, t = 2.184 and P = 0.050, healthy control group, t = 2.800 and P = 0.030) after incubation with HBeAg. TLR-2 also decreased under the stimulation of HBeAg with anti-HBe antibody, but there was no statistical difference compared with incubation with HBeAg alone (P > 0.05). Conclusions HBeAg could increase the negative costimulatory molecule B7-H1, inhibit TLR-2 and IFN-g, these lead to the reduced capacity of specific CTLs in viral clearance. [594.35 (133.75 1337.00) IU/mL], and there were statistically significant different (c 2 = 24.394, P < 0.001). Moreover, HBsAg titre was significantly higher in CHB than LC (Z = 3.754, P < 0.001), CHB had significantly higher HBsAg titre than HCC (Z = 4.630, P < 0.001), however, LC and HCC had no statistically significant different (Z = 1.720, P = 0.085). In HBeAg positive patients, HBsAg titre decreased from CHB [3259.83 (1710.60 7547.85 herbal ingredients, which was used for all patients. The sub-prescription consists of 2 4 herbal ingredients, which was used for patients based on their different symptoms. The patients took the decocted CHCP two times each day at least half one hour after meals. Results: Of 32 CHCP-treated patients, ten (31.2%) have obtained HBeAg seroconversion, ALT normalization, and with HBV DNA <1000copies/mL (lower limit of detection). These patients' baseline average characters were Age = 25.8 years old, ALT = 197.74U/L, HBV DNA = 5.71e7 copies/ml, and HBeAg = 551.25S/CO. The average time to achieve HBV DNA <1000 copies/ml was 72 weeks. The other 22 CHCP-treated patients' baseline average characters were Age = 35.5 years old, ALT = 148.75U/L, HBV DNA = 4.26e7copies/ml, and HBeAg = 796.99S/CO. For all CHCP-treated patients, neither demonstrated substitutions associated with NTCB resistance or the common adverse events and renal events. Conclusion: Two years CHCP anti-HBV Infection therapy is quite effective for the HBeAg positive younger patients whose baseline ALT >200U/L, HBeAg <500S/CO, and HBV DNA <1e8copies/ml. The CHCP is safe for long-term's anti-HBV infection personalized therapy.
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